Target Audience:

This activity has been designed to meet the educational needs of healthcare providers involved in the care of patients with nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Discuss the benefits and limitations of current diagnostic modalities and treatment options for NAFLD/NASH
  • Describe recent evidence regarding new and emerging noninvasive diagnostic modalities for NASH
  • Describe the mechanisms of action of novel agents for the treatment of NASH
  • Discuss recent evidence regarding the safety and efficacy of emerging agents for the treatment of NASH in diverse patient populations

Provided by

Supported by an educational grant from Novo Nordisk Inc. and Merck & Co., Inc.

In case you missed the symposium hosted during the
2022 NASH-TAG Conference...



Global Burden of Disease, Unmet Medical Needs, and Treatment Goals

Pathogenesis of NASH, Including Metabolic, Inflammatory, and Fibrotic Factors

Understanding the Diversity of Molecular Targets and Proposed Mechanism of Action of Late-Stage Treatment Modalities

Clinical Trial Results of Emerging Therapies in Late-Stage Development

Interactive Case Studies with Panel Discussion

  • Treating Obesity with NASH
  • Nuances of T2DM, Hypertension, and Dyslipidemia and Therapies
  • Considerations of Hormone Replacement/Supplementation


Closing Remarks


Director, NAFLD Research Center
Professor of Medicine, Director of Hepatology and
Vice Chief, Division of Gastroenterology
Adjunct Professor, Division of Epidemiology
University of California at San Diego
San Diego, California

Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, at University of California at San Diego. He is an internationally recognized thought leader in the management of nonalcoholic fatty liver disease and has established a thriving and vibrant center for clinical and research in NAFLD at UCSD.

Dr. Loomba is the founding director of the UCSD NAFLD Research Center. Along with his collaborators, he has led several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 50 clinical trials conducted worldwide. He holds two patents on non-invasive biomarkers of NAFLD and fibrosis

His research is funded by the National Institutes of Health including R01, U01, P30 and P01 grant mechanisms, Foundation of NIH, National Science Foundation as well as several investigator-initiated research projects funded by the industry. He is the Principal Investigator, UCSD, for the NIDDK-sponsored NASH Clinical Research Network. He served as the elected Chair of the NAFLD, Special Interest Group of the American Association for the Study of Liver Diseases. And is the elected member to the National Board of Directors of the American Liver Foundation.

He serves on the Editorial Board of Gastroenterology, Journal of Hepatology, GUT and Nature Reviews in Gastroenterology and Hepatology. He served as the Deputy Editor of HEPATOLOGY, the official journal of theAASLD, from 2017-2021.Dr. Loomba has published more than 300 manuscripts and has an H-index of 94. He is among the top 1% of the globally highly cited scientists across all fieldsin 2019 and 2020 by Web of Science. He is an elected member of American Society of Clinical Investigation.

UCSD Gastroenterology and Hepatology were listed as the number 1 research and education program in the World by the US World News ranking in 2021.


Co-founder of LipoNexus Inc.

Consultant: Aardvark Therapeutics, Inc., Altimmune, Alnylam/Regeneron, Amgen Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca, Bristol-Myer Squibb, CohBar, Inc., Eli Lilly, Galmed Pharmaceuticals, Gilead Sciences, Inc., Glympse Bio, Inc., HighTide Therapeutics Inc., Inipharma, Intercept Pharmaceuticals Inc., Inventiva, Ionis Pharmaceuticals, Janssen Inc., Madrigal Pharmaceuticals, Inc., Metacrine, Inc., NGM Biopharmaceuticals Inc., Novartis, Novo Nordisk Inc., Merck & Co., Inc., Pfizer Inc.,Sagimet Biosciences, Theratechnologies Inc., 89Bio Inc, Terns Pharmaceuticals , Inc., and Viking Therapeutics.

Research Grants: Aardvark Therapeutics, Inc., Astrazeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Gilead Sciences, Inc., Intercept Pharmaceuticals Inc., Hanmi Pharm.Co.,Ltd., Inventiva, Ionis Pharmaceuticals, Janssen, Madrigal Pharmaceuticals, Inc., Merck & Co., NGM Biopharmaceuticals, Novo Nordisk Inc., Pfizer Inc., Sonic Incytes, andTerns Pharmaceuticals.

Funding Support: NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515), NHLBI (P01HL147835), and NIAAA (U01AA029019).

Michael Charlton, MBBS, FRCP

Professor of Medicine
Chief of Hepatology, Director Transplant Institute
University of Chicago
Chicago, Illinois

Dr. Michael Charlton is a Fellow of the Royal College of Physicians. He serves as Chief of Hepatology, Director of the Center for Liver Diseases and Medical Director of the Transplant Institute at the University of Chicago. He is Past President of the International Liver Transplant Society. Dr. Charlton previously served as Director of Hepatology and Medical Director of Liver Transplantation at the Mayo Clinic. He has held editorial roles for leading journals, including, associate editor for Hepatology, Transplantation, American Journal of Transplantation, and Liver Transplantation, and was a founding Associate Editor for Clinical Gastroenterology and Hepatology. He has served as principal investigator on National Institutes of Health grants studying the pathophysiology of nonalcoholic steatohepatitis, developing a widely used small animal model of NASH. He is a lead investigator for national and international clinical trials in nonalcoholic steatohepatitis and viral hepatitis. He serves as a panel member and writer of AASLD Guidelines for the management of nonalcoholic steatohepatitis and has also served as a panel member and writer of AASLD Guidelines for the management of HCV. Dr. Charlton has authored over 200 original papers.


Consultant/Honorarium: Novo Nordisk Inc., AMRA Medical, Terns Pharmaceuticals, Inc., Fractyl Health Inc., Bristol-Myers Squibb, and CymaBay Therapeutics